Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPL500036 for Levodopa-Induced Dyskinesia in Parkinson's Disease
NCT05297201Phase 2Completed
- Sponsor
- Celon Pharma S.A.
- Start
- Nov 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of cpl500036 in levodopa-induced dyskinesia (LID), sponsored by Celon Pharma S.A.. Started Nov 2021; status: completed.
02
Drugs
cpl500036
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT05297201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297201.